We are a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. We use drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. Our agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen, or PSMA, in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. On September 29, 2017, we entered into a Development and License Agreement, or the License Agreement, with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH, or ABX, pursuant to which we acquired exclusive worldwide rights to develop and commercialize PSMA‑617 agents including the drug candidate known as 177Lu-PSMA‑617, a radioligand therapeutic, or RLT. Under the terms of the License Agreement, we will be responsible for, and bear the future costs of, worldwide development and commercialization of PSMA‑617, which ABX will supply. As consideration for the exclusive license, on September 29, 2017, we made an upfront cash payment of approximately $11.9 million to ABX, consisting of $12.0 million less an immaterial expense reimbursement amount, and issued to ABX 2,000,000 shares of our common stock and warrants to purchase, in the aggregate, 4,000,000 shares of our common stock. The License Agreement obligates us to pay ABX regulatory milestone payments of up to $25.0 million, sales milestone payments of up to $135.0 million, and tiered royalties based on percentages of net sales beginning in the mid-teens and not to exceed the mid-twenties.
Company profile
Ticker
ECYT
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
ECYT stock data
Latest filings (excl ownership)
15-12B
Securities registration termination
31 Dec 18
EFFECT
Notice of effectiveness
27 Dec 18
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Dec 18
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Dec 18
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Dec 18
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Dec 18
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Dec 18
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Dec 18
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Dec 18
POSASR
Automatic shelf registration (post-effective amendment)
21 Dec 18
Latest ownership filings
Institutional ownership, Q3 2021
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|